Evidence map›Paper›PMID 25023990›Full record

ArticleCarcinogenesis2014

Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis.

Lei Wang, Wenfang Li, Muqing Lin, Monika Garcia, David Mulholland, Michael Lilly, Manuela Martins-Green

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 90 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.Journal of cancer research and clinical oncology · 2023
    Review
  8. International journal of molecular sciences · 2023
    Article
  9. Review
  10. Review
  11. Review
  12. Cardio-Oncology: Mechanisms, Drug Combinations, and Reverse Cardio-Oncology.International journal of molecular sciences · 2022
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Prostate cancer: Therapeutic prospect with herbal medicine.Current research in pharmacology and drug discovery · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Lei WangDepartment of Cell biology and Neuroscience, University of California, Riverside, Riverside, CA 92521, USA, Department of Biomedical Engineering, School of Medicine, Shenzhen University, Guangdong 518060, China, Department of Molecular and Medical Pharmacology and Institute for Molecular Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA and Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Wenfang LiDepartment of Cell biology and Neuroscience, University of California, Riverside, Riverside, CA 92521, USA, Department of Biomedical Engineering, School of Medicine, Shenzhen University, Guangdong 518060, China, Department of Molecular and Medical Pharmacology and Institute for Molecular Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA and Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Muqing LinDepartment of Biomedical Engineering, School of Medicine, Shenzhen University, Guangdong 518060, China.
Monika GarciaDepartment of Cell biology and Neuroscience, University of California, Riverside, Riverside, CA 92521, USA, Department of Biomedical Engineering, School of Medicine, Shenzhen University, Guangdong 518060, China, Department of Molecular and Medical Pharmacology and Institute for Molecular Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA and Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
David MulhollandDepartment of Molecular and Medical Pharmacology and Institute for Molecular Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA and.
Michael LillyDepartment of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
Manuela Martins-GreenDepartment of Cell biology and Neuroscience, University of California, Riverside, Riverside, CA 92521, USA, Department of Biomedical Engineering, School of Medicine, Shenzhen University, Guangdong 518060, China, Department of Molecular and Medical Pharmacology and Institute for Molecular Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA and Department of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA manuela.martins@ucr.edu.
Medical University of South Carolina · USShenzhen University · CNUniversity of California, Los Angeles · USUniversity of California, Riverside · US

Funding

Chronic inhibition of androgen receptor signaling leads to neuroendocrine prostate cancer by trans differentiation of stem/progenitor cellsR01CA197910 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULHOLLAND, DAVID · 2015 to 2019
$2.0M
NCI NIH HHS R01 CA197910
6 · The paper itself

Abstract

Prostate cancer (PCa) is the second cause of cancer deaths in men in the USA. When the cancer recurs, early stages can be controlled with hormone ablation therapy to delay the rate of cancer progression but, over time, the cancer overcomes its hormone dependence, becomes highly aggressive and metastasizes. Clinical trials have shown that pomegranate juice (PJ) inhibits PCa progression. We have previously shown that the PJ components luteolin (L), ellagic acid (E) and punicic acid (P) together inhibit growth of hormone-dependent and -independent PCa cells and inhibit their migration and chemotaxis towards CXCL12, a chemokine that is important in PCa metastasis. On the basis of these findings, we hypothesized that L+E+P inhibit PCa metastasis in vivo. To test this possibility, we used a severe combined immunodeficiency mouse model in which luciferase-expressing human PCa cells were injected subcutaneously near the prostate. Tumor progression was monitored with bioluminescence imaging weekly. We found that L+E+P inhibits PC-3M-luc primary tumor growth, inhibits the CXCL12/CXCR4 axis for metastasis and none of the tumors metastasized. In addition, L+E+P significantly inhibits growth and metastasis of highly invasive Pten (-/-) ;K-ras (G12D) prostate tumors. Furthermore, L+E+P inhibits angiogenesis in vivo, prevents human endothelial cell (EC) tube formation in culture and disrupts preformed EC tubes, indicating inhibition of EC adhesion to each other. L+E+P also inhibits the angiogenic factors interleukin-8 and vascular endothelial growth factor as well as their induced signaling pathways in ECs. In conclusion, these results show that L+E+P inhibits PCa progression and metastasis.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicBiological ProductsChemokine CXCL12Ellagic AcidEndothelium, VascularHumansLinolenic AcidsLuteolinMaleMiceMice, Inbred C57BLMice, SCIDNeovascularization, PathologicProstatic NeoplasmsProto-Oncogene Proteins c-aktAntineoplastic Agents, PhytogenicBiological ProductsChemokine CXCL12Cxcl12 protein, mouseCXCR4 protein, mouseEllagic AcidLinolenic AcidsLuteolinProto-Oncogene Proteins c-aktpunicic acidReceptors, CXCR4

Identifiers

PMID25023990
PMCPMC6276919
OpenAlexW2032280159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.